期刊文献+

五种基因多态性对华法林用量个体差异影响的研究 被引量:20

Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose
原文传递
导出
摘要 目的探讨维生素K环氧化物还原酶复合体亚单位1基因(vitaminKepoxidereductasecomplexsubunit1,VKORCl)、细胞色素P4502C9基因(cytochromeP4502C9,CYP2C9)、-/-谷氨酰羧化酶基因(gamma—glutamylcarboxylase,GGCX)、微粒体环氧化物水解酶基因(microsomalepoxidehydrolase1,EPHXl)和载脂蛋白E基因(apolipoproteinE,APOE)多态性与个体间华法林稳定剂量差异的关系。方法收集249例已获得华法林稳定剂量患者的临床资料及血样,采用聚合酶链反应-变性高效液相色谱技术,检测5种基因的基因型。比较不同基因型患者间华法林稳定剂量的差异,结合非遗传因素,建立华法林稳定剂量的预测算法。结果5种基因中与华法林稳定剂量相关的有VKORCl、CYP2C9和C,GCX。多元回归分析提示对华法林用量个体差异有显著影响的因素有年龄、体重、VKORCl、CYP2C9和GGCX。根据最佳回归模型得到的华法林稳定剂量预测算法可解释华法林稳定剂量个体差异57.8%的原因。VKORCl,CYP2C9,GGCX,年龄、体重对华法林用量个体差异的贡献分别是30.2%、22.8%、1.5%、4.7%和6.7%。结论遗传因素是影响华法林个体间用量差异的主要因素;华法林稳定剂量预测算法可提高临床上华法林使用的有效性和安全性。 Objective To investigate the effect of genetic polymorphisms in VKORC1, CYP2Cg, GGCX, EPHX1, APOE genes on inter-individual variation in warfarin maintenance dose. Methods Two hundred and forty-nine patients with stable warfarin dose were enrolled in this study, and the clinical data and blood samples of the patients were collected. Genotypes for the 5 genes were determined by using PCR and denaturing high performance liquid chromatography (DHPLC) assay. The warfarin maintenance doses were compared among patients with different genotypes of the 5 genes, and a warfarin stable dosing algorithm was derived based on genetic and non-genetic factors. Results Of the 5 genes, VKORC1, CYP2C9 and GGCX were associated with warfarin stable dose. The multiple linear regression analysis indicated that VKORC1, CYP2C9 and GGCX genes, age and weight, had significant influence on inter- individual variation in warfarin stable dose, which contributed 30.2%, 22.8%, 1.5%, 4.7% and 6.7% respectively. The warfarin stable dosing algorithm acquired from the optimal regression model could explain 57.8% variation in warfarin dose. Conclusion This study suggested that genetic factors are the major determinants of the warfarin maintenance dose, and warfarin stable dosing algorithm may be useful for helping clinicians to prescribe warfarin with greater safety and efficiency.
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2011年第6期661-665,共5页 Chinese Journal of Medical Genetics
基金 基金项目:贵州省科技厅基金资助项目(黔科合J字[2008]2296)
关键词 遗传因素 华法林 药物遗传 个体化用药 genetic factor warfarin pharmacogenetics personalized medicine
  • 相关文献

参考文献19

  • 1Yu HC, Chan TY, Critchely JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM, 1996, 89:127-135.
  • 2Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000, 34 : 1395-1401.
  • 3Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J, 2003, 3: 202-214.
  • 4Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 5Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005,106 : 2329-2933.
  • 6Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics, 2009, 19: 226-234.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta, 2004,348:57-61.
  • 9Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmaeogenomics J, 2005, 5: 262-270.
  • 10Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet, 2007,121:23-34.

二级参考文献5

  • 1Pedersen JC, Berg K. Gene-gene interaction between the low density lipoprotein receptor and apolipoprotein E loci affects lipid levels[ J]. Clin Genet, 1990,38 (4) : 287-294.
  • 2Eggertsen G, Tegelman R, Ericsson S, et al. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations [ J ]. Clin Chem, 1993,39(10) :2125-2129.
  • 3Zeng Y, Miao F, Li L, et al. A rapid and accurate DHPLC assay for determination of apolipoprotein E gcnotypes [J]. J Alzheimers Dis, 2007,12(4) :357-363.
  • 4孙丽娜,张波,许颖,周晓星,黄莉莉,卓淑雨,苏宜香.广州市40~65岁居民载脂蛋白E基因多态性与血脂水平的关系[J].中山大学学报(医学科学版),2008,29(2):181-185. 被引量:5
  • 5黎旭,赵冬,刘静,刘飒,刘军,秦兰萍,吴兆苏.北京自然人群载脂蛋白E基因多态性频率分布研究[J].首都医科大学学报,2003,24(3):268-271. 被引量:13

同被引文献273

引证文献20

二级引证文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部